Two U.S.-based companies are teaming up to advance personalized human-based disease models that could help speed the discovery of novel therapies for rare diseases, such as aromatic L-amino acid decarboxylase (AADC) deficiency. Ixcells Biotechnologies and Rosebud Biosciences, both headquartered in California, have entered into a partnership to develop…